Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 4,242 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Deficiency Disorder Clear all
Completed Phase 1 Interventional

Study of Topical ABI-1968 in Subjects With Precancerous Anal Lesions Resulting From Human Papillomavirus (HPV) Infection

NCT03202992
View directory record Official record
Conditions
HSIL, High-Grade Squamous Intraepithelial Lesions, Human Papilloma Virus Infection, HIV Infection, Anal Cancer, Anus Neoplasms
Interventions
ABI-1968
Drug
Lead sponsor
Antiva Biosciences
Industry
Eligibility
27 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
5
States / cities
San Francisco, California • Orlando, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 20, 2026, 5:59 AM EDT
Completed No phase listed Observational

Collection of Blood Samples From HIV Infected People

NCT00096772
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
2,502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
83
States / cities
Mill Valley, California • Oakland, California • San Francisco, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients

NCT00002128
View directory record Official record
Conditions
HIV Infections
Interventions
Adefovir dipivoxil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 60 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 1Phase 2 Interventional

CCR5-modified CD4+ T Cells for HIV Infection

NCT03666871
View directory record Official record
Conditions
HIV Infections
Interventions
SB-728-T, Expanded unmodified autologous CD4+ T cells
Biological
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 21, 2024 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

A Study of Peldesine (BCX-34) in HIV-Infected Patients

NCT00002237
View directory record Official record
Conditions
HIV Infections
Interventions
Peldesine
Drug
Lead sponsor
BioCryst Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin D-Enriched Mushrooms on Vitamin D Status and Immune Function and Inflammatory Status in Adults

NCT05559112
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Vitamin D-enriched mushrooms, Study Powder
Other
Lead sponsor
Purdue University
Other
Eligibility
30 Years to 69 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 20, 2026, 5:59 AM EDT
Enrolling by invitation Phase 1Phase 2 Interventional

Base-Edited Hematopoietic Stem/Progenitor Cell X-Linked Severe Combined Immunodeficiency Gene Therapy

NCT06851767
View directory record Official record
Conditions
X-linked Severe Combined Immunodeficiency, X-SCID, XSCID
Interventions
Plerixafor, Filgrastim, Palifermin, Busulfan, Base-edited hematopoietic stem and progenitor cells
Genetic · Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult Participants

NCT01082692
View directory record Official record
Conditions
HIV-1 Infection, HIV Infections
Interventions
PENNVAX-B
Biological
Lead sponsor
Inovio Pharmaceuticals
Industry
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Oct 20, 2026, 5:59 AM EDT
Terminated Not applicable Interventional

Evaluation of an Intervention on Adherence to Highly Active Antiretroviral Therapy (HAART) in HIV Infected Adults

NCT00203853
View directory record Official record
Conditions
HIV Infections
Interventions
pillbox, wristwatch
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

A Phase I Trial of Tecogalan Sodium ( DS-4152 ) Administered as an Infusion Weekly x 4

NCT00002137
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Tecogalan sodium
Drug
Lead sponsor
Daiichi Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Sleep, HIV Disease Progression, and Function in HIV Infected Children and Adolescents

NCT00253695
View directory record Official record
Conditions
Sleep, HIV Infections
Interventions
Wrist Actigraphy
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
8 Years to 17 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 28, 2013 · Synced Oct 20, 2026, 5:59 AM EDT
Active, not recruiting Not applicable Interventional

The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City

NCT06316739
View directory record Official record
Conditions
HIV Infections, HCV, Overdose
Interventions
Ganchero intervention
Behavioral
Lead sponsor
North Jersey AIDS Alliance dba North Jersey Community Research Initiative (NJCRI)
Other
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.

NCT00931801
View directory record Official record
Conditions
HIV
Interventions
atazanavir/raltegravir, atazanavir/tenofovir/emtricitabine
Drug
Lead sponsor
Community Research Initiative of New England
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Not applicable Interventional

A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS

NCT00002330
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
Roche Global Development
Other
Eligibility
13 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
35
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA)

NCT01910402
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus, HIV Infections
Interventions
Dolutegravir/abacavir/lamivudine FDC, Atazanavir, Ritonavir, Tenofovir/emtricitabine FDC
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Personalized Text Messages to Improve Antiretroviral Treatment (ART) Adherence in HIV+ Methamphetamine Users

NCT01317277
View directory record Official record
Conditions
HIV, AIDS
Interventions
individualized Texting for Adherence Building (iTAB), Psychoeducation
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2021 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Partner and Social Contact Referral: iKnow

NCT02467439
View directory record Official record
Conditions
Acute HIV Infection, HIV Seropositive, Sexually Transmitted Infections
Interventions
Notification cards
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15,310 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 26, 2019 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 1 Interventional

Study of How Indinavir (an Anti-HIV Drug) and Rifabutin (a Drug Used to Treat MAC, an HIV-Associated Disease) Interact in HIV-Positive and HIV-Negative Adults

NCT00000877
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Rifabutin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
8
States / cities
Los Angeles, California • Denver, Colorado • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Not applicable Interventional

A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Recent HIV Infection

NCT00002177
View directory record Official record
Conditions
HIV Infections
Interventions
Hydroxyurea, Nelfinavir mesylate, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
16 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

NCT00008528
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 20, 2026, 5:59 AM EDT
Completed No phase listed Observational

Specimens From Normal Controls

NCT00341211
View directory record Official record
Conditions
Viral Infections
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 20, 2026, 5:59 AM EDT
Completed Phase 3 Interventional

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

NCT00002371
View directory record Official record
Conditions
HIV Infections
Interventions
Indinavir sulfate, Lamivudine, Stavudine, Zidovudine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
5
States / cities
Torrance, California • Tampa, Florida • Stony Brook, New York + 2 more
Source: ClinicalTrials.gov public record
Updated May 4, 2011 · Synced Oct 20, 2026, 5:59 AM EDT
Recruiting Not applicable Interventional

Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study

NCT04949464
View directory record Official record
Conditions
HIV Infection, Tobacco-Related Carcinoma
Interventions
Computed Tomography, Smoking Cessation Intervention
Procedure · Behavioral
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
45 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
11
States / cities
La Jolla, California • Washington D.C., District of Columbia • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy

NCT02194998
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT), Dasabuvir (DSV), Ribavirin (RBV)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
15
States / cities
Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 20, 2026, 5:59 AM EDT